Endoskopia Sp. z o.o. — Clinical Trial Site

48 Registered trials

19 Currently recruiting

Organisation

Endoskopia Sp. z o.o.

Location

Sopot, Poland

Identifier

ORG-100045318

Address

Ul. Boleslawa Chrobrego 6/8, 81-756, Poland

Departments

Endoscopy Limited Liability Company
Endoskopia
Endoskopia Sp. z o.o.
Endoskopia Sp.z.o.o
ENDOSKOPIA Spółka z Ograniczoną Odpowiedzialnością, Poradnia Gastroenterologiczna
Gastroeneterolgy
Gastroenterologia
Gastroenterology
Gastroenterology Department
N/A
NA
PL10009: Gastroenterology
PL10016: Poradnia Gastroenterologiczna
PL10018: Poradnia Gastroenterologiczna
Poradnia gastroenterologiczna
private clinic

Clinical trials at this site (48)

Search interface

A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended

2023-508636-61-00 Crohn’s Disease 5 2024-10-24
A clinical trial to assess the safety and effects of AGMB-129 compared to placebo in patients with fibrostenotic Crohn’s disease. Ended

2022-502789-26-01 Fibrostenotic Crohn’s Disease 4 2023-11-03
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-515027-11-00 Crohn’s disease 4 2023-06-29
A Phase 2b Study to Evaluate MORF-057 in Adults with Moderately to Severely Active UC Ended

2022-500953-17-00 Moderately to severely active ulcerative colitis 4 2023-03-23
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504741-32-00 Moderately to Severely Active Crohn's Disease 4 2022-11-30
Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended

2023-504743-13-00 Moderately to Severely Active Ulcerative Colitis 4 2022-11-30
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended

2022-502841-91-00 Crohn’s Disease 5 2020-08-12
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended

2023-504718-31-00 Moderately to Severely Active Ulcerative Colitis 10 2019-10-19
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Ended

2023-506994-36-00 Ulcerative Colitis 5 2018-10-11
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended

2023-504736-18-00 Moderately to Severely Active Crohn's Disease 10 2018-07-26
Long Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis. Ended

2023-505699-31-00 Ulcerative Colitis 5 2017-01-02
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis Ended

2023-510324-77-00 Ulcerative colitis 1 2024-10-20
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis Ended

2023-508679-34-00 Ulcerative Colitis 4 2024-07-30
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis Ended

2023-506655-19-00 Ulcerative Colitis (UC) 4 2024-05-16
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended

2022-503005-38-00 Ulcerative Colitis 4 2023-12-04
A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and … Ended

2022-502778-18-00 ulcerative colitis 5 2023-11-17
A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjectswith moderate to severe ulcerative colitis Ended

2022-501263-41-00 Ulcerative Colitis 4 2023-08-10
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients with Mild-to-Moderate Ulcerative Colitis Ended

2024-512558-40-00 Mild-to-moderate ulcerative colitis 4 2023-05-11
A Phase 1 Study to Evaluate the Safety and Target Engagement of EXL01 in the Maintenance of Steroid-induced Clinical Response or Remission … Ended

2022-502241-99-00 Crohn's Disease 1 2023-03-20
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn’s Disease Ended

2024-511089-36-00 Crohn’s disease 4 2023-03-17
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended

2023-510195-31-00 Idiopathic or Diabetic Gastroparesis 4 2023-01-03
VERDICT - Optimal Treatment Target in Active Ulcerative Colitis (UC) Ended

2024-514183-21-00 Ulcerative colitis 6 2021-01-15